RNL Bio successfully treated a race horse with ligament injury using fat derived stem cell

Feb. 13, 2009 - PRLog -- RNL Bio Co., Ltd., a leading biopharmaceutical company dedicated to development of adult stem cell therapeutics, announced on Feb 12 that horse’s syndesmitis, one of obstinate diseases, was successfully cured by RNL’s stem cell therapeutics. The hero is White Light that was in the news when he received stem cell therapy for the first time as a horse patient in Korea. As White Light shows great improvement in rehabilitation, he is expected to return to the race track around May.
Syndesmitis in horses is one of obstinate diseases. So many fine horses left race tracks because of this kind of disease. Injury in ligaments is a fetal disease not only race horses but also athletes. Athletes easily get damages in ligaments and tendons due to the nature of their abrupt movements. Damage like torn anterior cruciate ligament ankle ligament injury may ruin a season or even lifetime as an athlete. Conventional treatment of these injuries is surgery and medication but long time rehabilitation is required. This new stem cell therapy for ligament injury is good news to athletes.
Dr. Jeong-Chan Ra, CEO of RNL Bio said “to get efficient treatment using stem cells, preservation of stem cells is recommended when you are younger and healthier. We will try harder to find cures using stem cells of more obstinate diseases”
RNL Bio has operated a stem cell bank that isolates stem cells from patients’ own fat tissue and preserves them for a long time.

# # #

RNL is a premier biotech company in Korea focused on stem cell therapeutics. Headquartered in Seoul with a recently opened state-of-the-art GMP facility, RNL is a publicly traded company on the Korean Stock Exchange (Code 003190)